checkAd

     393  0 Kommentare BioXcel Therapeutics Announces Termination of Proposed Public Offering - Seite 2

    Contact Information

    Corporate

    BioXcel Therapeutics
    Erik Kopp
    1.203.494.7062
    ekopp@bioxceltherapeutics.com

    Investor Relations
    BioXcel Therapeutics
    Brennan Doyle
    1.475.355.8462
    bdoyle@bioxceltherapeutics.com

    Media
    Russo Partners
    David Schull
    T: 858-717-2310
    David.schull@russopartnersllc.com
    Scott Stachowiak
    T: 646-942-5630
    Scott.stachowiak@russopartnersllc.com

    Source: BioXcel Therapeutics, Inc.

    BT BIOXCEL THERAPEUTICS is a registered trademark of BioXcel Therapeutics, Inc.
    All other trademarks are the properties of their respective owners.
    Copyright 2024, BioXcel Therapeutics, Inc. All rights reserved.


    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    BioXcel Therapeutics Announces Termination of Proposed Public Offering - Seite 2 NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) - BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced …